In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N‐of‐1 studies
- 9 January 2017
- journal article
- research article
- Published by Wiley in Pediatric Pulmonology
- Vol. 52 (4) , 472-479
Abstract
Summary: Rationale: Ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, decreases sweat chloride concentration, and improves pulmonary function in 6% of cystic fibrosis (CF) patients with specific CFTR mutations. Ivacaftor increases chloride transport in many other CFTR mutations in non‐human cells, if CFTR is in the epithelium. Some CF patients have CFTR in the epithelium with residual CFTR function. The effect of ivacaftor in these patients is unknown.Methods: This was a series of randomized, crossover N‐of‐1 trials of ivacaftor and placebo in CF patients ≥8 years old with potential residual CFTR function (intermediate sweat chloride concentration, pancreatic sufficient, or mild bronchiectasis on chest CT). Human nasal epithelium (HNE) was obtained via nasal brushing and cultured. Sweat chloride concentration change was the in vivo outcome. Chloride current change in HNE cultures with ivacaftor was the in vitro outcome.Results: Three subjects had decreased sweat chloride concentration (−14.8 to −40.8 mmol/L, P < 0.01). Two subjects had unchanged sweat chloride concentration. Two subjects had increased sweat chloride concentration (+23.8 and +27.3 mmol/L, P < 0.001); both were heterozygous for A455E and pancreatic sufficient. Only subjects with decreased sweat chloride concentration had increased chloride current in HNE cultures.Conclusions: Some CF patients with residual CFTR function have decreased sweat chloride concentration with ivacaftor. Increased chloride current in HNE cultures among subjects with decreased sweat chloride concentrations may predict clinical response to ivacaftor. Ivacaftor can increase sweat chloride concentration in certain mutations with unclear clinical effect. Pediatr Pulmonol. 2017;52:472–479.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (P30‐DK072517)
- National Institute of General Medical Sciences (T32‐GM007546)
This publication has 45 references indexed in Scilit:
- Modeling Cystic Fibrosis Using Pluripotent Stem Cell-Derived Human Pancreatic Ductal Epithelial CellsStem Cells Translational Medicine, 2016
- Cystic fibrosis genetics: from molecular understanding to clinical applicationNature Reviews Genetics, 2014
- Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expressionScience Translational Medicine, 2014
- A Little CFTR Goes a Long Way: CFTR-Dependent Sweat Secretion from G551D and R117H-5T Cystic Fibrosis Subjects Taking IvacaftorPLOS ONE, 2014
- Correcting the Cystic Fibrosis Disease Mutant, A455E CFTRPLOS ONE, 2014
- VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1Molecular Biology of the Cell, 2013
- Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR MutationChest, 2012
- Directed differentiation of human pluripotent stem cells into mature airway epithelia expressing functional CFTR proteinNature Biotechnology, 2012
- CFTR: folding, misfolding and correcting the ΔF508 conformational defectTrends in Molecular Medicine, 2012
- Spirometric Reference Values from a Sample of the General U.S. PopulationAmerican Journal of Respiratory and Critical Care Medicine, 1999